---
title: "江苏康为世纪生物科技股份有限公司 (688426.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/688426.SH.md"
symbol: "688426.SH"
name: "江苏康为世纪生物科技股份有限公司"
industry: "生物技术"
---

# 江苏康为世纪生物科技股份有限公司 (688426.SH)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 沪深市场 |
| Website | [www.cwbio.com](https://www.cwbio.com) |

## Company Profile

公司是一家立足于生命科学和大健康领域，具有自主知识产权的国家高新技术企业。公司于 2022 年成功登陆上交所科创板。公司秉承 “让每一个生命健康有为” 的使命，始终致力于分子检测核心原料酶的自主研发并实现进口替代，在分子检测领域积累了丰富的技术研发优势并获得过百项专利技术，参与了多项国家标准和行业标准的开发和制定，为多个生命科学细分领域提供超过 700 款创新型产品。公司立足分子检测底层核心技术的自主研发，在原料酶、核酸保存、样本前处理领域有十余年的研发积累，是国内少数实现分子检测核心环节完整业务布局的生物科技企业。公司的核心产品包括分子检测酶原料、核酸保存试剂、核酸提取纯化试剂以及分子诊断试...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:09.000Z

**Overall: C (0.47)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 58 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 41.46% |  |
| Net Profit YoY | 4.70% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.99 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.77B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 167.16M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -9.42% | D |
| Profit Margin | -82.39% | E |
| Gross Margin | 45.87% | B |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 41.46% | A |
| Net Profit YoY | 4.70% | C |
| Total Assets YoY | -7.16% | D |
| Net Assets YoY | -9.06% | D |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -121.38% | D |
| OCF YoY | 41.46% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.10 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 9.14% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 江苏康为世纪生物科技股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-9.42%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-82.39%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "45.87%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "41.46%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "4.70%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-7.16%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-9.06%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-121.38%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "41.46%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.10",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "9.14%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 百济神州-U (SH.688235) | C | A | B | C | A | B |
| 02 | 甘李药业 (SH.603087) | B | B | D | A | B | B |
| 03 | 三生国健 (SH.688336) | A | B | D | B | C | B |
| 04 | 百奥赛图 (SH.688796) | A | A | C | D | B | B |
| 05 | 天坛生物 (SH.600161) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -20.13 | 53/83 | - | - | - |
| PB | 1.99 | 23/83 | 2.20 | 1.89 | 1.58 |
| PS (TTM) | 16.59 | 61/83 | 21.21 | 18.31 | 16.61 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/688426.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/688426.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/688426.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.